WO2010082804A3 - Method for producing physiologically active protein or peptide using immunoglobulin fragment - Google Patents

Method for producing physiologically active protein or peptide using immunoglobulin fragment Download PDF

Info

Publication number
WO2010082804A3
WO2010082804A3 PCT/KR2010/000342 KR2010000342W WO2010082804A3 WO 2010082804 A3 WO2010082804 A3 WO 2010082804A3 KR 2010000342 W KR2010000342 W KR 2010000342W WO 2010082804 A3 WO2010082804 A3 WO 2010082804A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
physiologically active
active protein
immunoglobulin fragment
producing physiologically
Prior art date
Application number
PCT/KR2010/000342
Other languages
French (fr)
Other versions
WO2010082804A2 (en
Inventor
Jin-Sun Kim
Sung Youb Jung
Jong-Soo Lee
Byung Sun Lee
Se Chang Kwon
Gwan Sun Lee
Original Assignee
Hanmi Holdings Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co., Ltd filed Critical Hanmi Holdings Co., Ltd
Publication of WO2010082804A2 publication Critical patent/WO2010082804A2/en
Publication of WO2010082804A3 publication Critical patent/WO2010082804A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a method for mass-producing a physiologically active protein or peptide using a fusion protein composed of the physiologically active protein or peptide and an immunoglobulin fragment. The present invention also provides such a fusion protein, a DNA encoding the fusion protein, an expression vector comprising the DNA, and a microorganism transformed with the expression vector.
PCT/KR2010/000342 2009-01-19 2010-01-19 Method for producing physiologically active protein or peptide using immunoglobulin fragment WO2010082804A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090004234 2009-01-19
KR10-2009-0004234 2009-01-19

Publications (2)

Publication Number Publication Date
WO2010082804A2 WO2010082804A2 (en) 2010-07-22
WO2010082804A3 true WO2010082804A3 (en) 2010-11-25

Family

ID=42340231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/000342 WO2010082804A2 (en) 2009-01-19 2010-01-19 Method for producing physiologically active protein or peptide using immunoglobulin fragment

Country Status (4)

Country Link
KR (1) KR20100084996A (en)
AR (1) AR075029A1 (en)
TW (1) TW201031752A (en)
WO (1) WO2010082804A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1759001T3 (en) 2004-04-21 2011-08-01 Enobia Pharma Inc Conjugate for Bone Delivery and Method of Preparation by Targeting Proteins to the Bone
JP6055779B2 (en) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド Composition comprising natriuretic peptide and method of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
RU2708068C2 (en) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Treating convulsions using recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
RU2745528C2 (en) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Production of alkaline phosphatases
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017173413A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
JP7018933B2 (en) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド How to treat bronchomalacia
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
JP2021519590A (en) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド Glycoprotein production
KR102124035B1 (en) * 2018-09-18 2020-06-19 한국생산기술연구원 A expression cassette for preparation of thymulin and use thereof
WO2020060202A1 (en) * 2018-09-18 2020-03-26 한국생산기술연구원 Expression cassette for preparing thymulin or argireline, and use thereof
CN111208243B (en) * 2018-11-21 2022-05-17 中国科学院大连化学物理研究所 Anion exchange chromatographic column-based SUMO peptide fragment enrichment method

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196321A (en) * 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US20050124045A1 (en) * 2001-08-17 2005-06-09 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with increased biological activities
US20060269553A1 (en) * 2003-11-13 2006-11-30 Hanmi Pharm. Ind. Co., Ltd. Protein complex using an immunoglobulin fragment and method for the preparation thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196321A (en) * 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US20050124045A1 (en) * 2001-08-17 2005-06-09 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with increased biological activities
US20060269553A1 (en) * 2003-11-13 2006-11-30 Hanmi Pharm. Ind. Co., Ltd. Protein complex using an immunoglobulin fragment and method for the preparation thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LO K. M. ET AL, PROTEIN ENGINEERING, vol. 11, no. 12, June 1998 (1998-06-01), pages 495 - 500 *

Also Published As

Publication number Publication date
KR20100084996A (en) 2010-07-28
WO2010082804A2 (en) 2010-07-22
AR075029A1 (en) 2011-03-02
TW201031752A (en) 2010-09-01

Similar Documents

Publication Publication Date Title
WO2010082804A3 (en) Method for producing physiologically active protein or peptide using immunoglobulin fragment
WO2010042654A3 (en) Recombinant nell protein production
WO2013184939A3 (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
WO2011064758A3 (en) Fusion proteins of immunoglobulin fc and interferon- alpha
WO2009142460A3 (en) Antibody-peptide fused synergibody
WO2008140812A3 (en) Compositions and methods comprising klk3, psca, or folh1 antigen
IL195191A (en) Fusion proteins, nucleic acids encoding same and processes for producing same
WO2006127757A3 (en) Interferon-igg fusion
WO2013059885A3 (en) Polypeptide constructs and uses thereof
AU2010325787A8 (en) Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
WO2009009523A3 (en) Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2012142515A3 (en) Fc fusion proteins comprising novel linkers or arrangements
WO2012048332A3 (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
IL197459A (en) Humanized proteins, including antibodies and methods for producing the same
WO2007001264A3 (en) Method of making recombinant human antibodies for use in biosensor technology
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
NZ596735A (en) Recombinant production of peptides
WO2008100470A3 (en) Rage - immunoglobulin fusion proteins
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
EP3976642A4 (en) Apoe antibodies, fusion proteins and uses thereof
WO2012012351A3 (en) High-protein beverages comprising whey protein
WO2008085900A3 (en) Methods for generating novel stabilized proteins
WO2007115724A3 (en) Method of increasing the in vivo recovery of therapeutic polypeptides
WO2016130628A8 (en) Griffithsin mutants
WO2011098999A3 (en) Chemical preparation of ubiquitin thioesters and modifications thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10731419

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10731419

Country of ref document: EP

Kind code of ref document: A2